BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...amaurosis 1. Atsena co-founder and CSO Shannon Boye had developed the adeno-associated viral vector delivering GUCY2D...
...Partner” ). Targets GUCY2D - Guanylate cyclase 2D membrane retina-specific BioCentury Staff Sanofi University of Florida Praxis Precision Medicines Inc. CureVac AG Inhibrx Harmony Biosciences LLC Guanylate cyclase 2D membrane retina-specific (GUCY2D) Atsena...
BioCentury | Mar 1, 2019
Company News

Bausch wins $195M bid to acquire bankrupt Synergy's assets

Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) won a $195 million bid to acquire assets of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) in a court-supervised bankruptcy auction. Synergy markets gastrointestinal drug Trulance plecanatide. Trulance is an uroguanylin analog...
BioCentury | Jan 18, 2019
Clinical News

China approves Linzess for IBS-C

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said China's National Medical Products Administration approved Linzess linaclotide to treat irritable bowel syndrome with constipation (IBS-C). The company expects to launch the guanylate cyclase C (GCC; GUCY2C) agonist in China...
BioCentury | Dec 21, 2018
Company News

Bausch named 'stalking horse' in Synergy auction

Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) bid $200 million to acquire selected assets of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) in a court-supervised bankruptcy auction, including global rights to gastrointestinal drug Trulance plecanatide. The agreement makes Bausch...
BioCentury | Nov 2, 2018
Company News

Synergy evaluating options following slow Trulance uptake

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) said it is evaluating strategic alternatives, including seeking bankruptcy protection, following slower-than-anticipated sales of gastrointestinal drug Trulance plecanatide. The company said it is projecting net sales for Trulance for 2018 of...
BioCentury | Nov 2, 2018
Company News

Linzess growth figures disappoint investors

Allergan plc (NYSE:AGN) said it expects future growth for Linzess linaclotide to be in the low- to mid-single digits, sending shares of partner Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) down $2.91 (18%) to $13.18 on Oct. 30....
BioCentury | Oct 30, 2018
Company News

Linzess growth figures disappoint investors

Allergan plc (NYSE:AGN) said it expects future growth for Linzess linaclotide to be in the low- to mid-single digits, sending shares of partner Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) down $2.91 (18%) to $13.18. Allergan, which relayed...
BioCentury | Aug 10, 2018
Company News

Luoxin gains Chinese rights to Trulance

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (Linyi, China) exclusive rights to develop and commercialize gastrointestinal drug Trulance plecanatide in China, including Hong Kong and Macau. The license covers the...
BioCentury | Aug 7, 2018
Company News

Luoxin gains Chinese rights to Trulance

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (Linyi, China) exclusive rights to develop and commercialize gastrointestinal drug Trulance plecanatide in China, including Hong Kong and Macau. The license covers the...
BioCentury | Jul 21, 2018
Product Development

Getting to the point in IBS

A large epidemiological study set Ironwood Pharmaceuticals Inc. on a path to finding symptomatic outcomes important to IBS-C patients. The company’s new Phase IIIb study of Linzess linaclotide will probe those outcomes, seeking results that...
Items per page:
1 - 10 of 182